Sight Sciences, Inc. (NASDAQ:SGHT) Insider Matthew Link Sells 20,734 Shares

Sight Sciences, Inc. (NASDAQ:SGHT) insider Matthew Link sold 20,734 shares of the company’s stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $5.91, for a total value of $122,537.94. Following the completion of the transaction, the insider now directly owns 726,838 shares in the company, valued at $4,295,612.58. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Sight Sciences Price Performance

Shares of SGHT traded up $0.02 during trading hours on Friday, reaching $5.97. The stock had a trading volume of 125,111 shares, compared to its average volume of 193,555. Sight Sciences, Inc. has a 12 month low of $1.04 and a 12 month high of $8.45. The stock has a market capitalization of $297.04 million, a PE ratio of -5.33 and a beta of 2.71. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.50 and a current ratio of 11.01. The company’s 50-day moving average is $6.31 and its two-hundred day moving average is $6.28.

Sight Sciences (NASDAQ:SGHT) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.06. Sight Sciences had a negative return on equity of 45.68% and a negative net margin of 65.90%. The company had revenue of $21.37 million during the quarter, compared to analysts’ expectations of $21.32 million. During the same period in the prior year, the company earned ($0.30) EPS. Research analysts expect that Sight Sciences, Inc. will post -1 EPS for the current year.

Wall Street Analyst Weigh In

SGHT has been the topic of a number of analyst reports. Lake Street Capital initiated coverage on Sight Sciences in a research report on Wednesday, August 21st. They set a “buy” rating and a $10.00 price target on the stock. Citigroup increased their price target on Sight Sciences from $6.00 to $6.50 and gave the stock a “neutral” rating in a research report on Wednesday, July 10th. Morgan Stanley increased their price target on Sight Sciences from $5.40 to $6.50 and gave the stock an “equal weight” rating in a research report on Monday, July 15th. Finally, Needham & Company LLC restated a “hold” rating on shares of Sight Sciences in a research note on Friday, August 2nd. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $7.25.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Steele Capital Management Inc. bought a new position in shares of Sight Sciences in the 2nd quarter valued at $67,000. State Board of Administration of Florida Retirement System bought a new position in Sight Sciences during the 1st quarter worth $59,000. SG Americas Securities LLC bought a new position in Sight Sciences during the 3rd quarter worth $75,000. The Manufacturers Life Insurance Company bought a new position in Sight Sciences during the 2nd quarter worth $95,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in Sight Sciences by 51.9% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,653 shares of the company’s stock worth $141,000 after purchasing an additional 9,106 shares during the last quarter. 55.51% of the stock is currently owned by institutional investors.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.